Table 3.

Relative risk of hepatotoxicity associated with MMI/CBM compared with PTU

	Number of users	Number of events	Crude HR (95% CI)	Adjusted HR (95% CI)*
Hepatitis
PTU	24 941	21	1.00	1.00
MMI/CBM	46 438	118	2.91 (1.83, 4.63)	2.89 (1.81, 4.60)†
Acute liver failure
PTU	24 941	12	1.00	1.00
MMI/CBM	46 438	12	0.50 (0.22, 1.10)	0.54 (0.24, 1.22)
Cholestasis
PTU	24 941	4	1.00	1.00
MMI/CBM	46 438	9	1.10 (0.34, 3.59)	1.14 (0.40, 3.72)

CBM, carbimazole; CI, confidence interval; HR, hazard ratio; MMI, methimazole; PTU, propylthiouracil.

^*Adjusted for all variables listed in Table 1, with the exceptions of history of hyperthyroidism, hyperlipidaemia and use of neurological drugs for the outcome of acute liver failure as well as presence of pregnancy and chronic kidney diseases for the cholestasis outcome due to small sample size.

^†P < 0.05.